This Cancer Center Support Grant application from the University of Pittsburgh Cancer Institute, an NCI-designated Comprehensive Cancer Center, seeks support for years 22-26. The UPCI is organized as a matrix center that integrates cancer research, clinical care, and cancer outreach across the University of Pittsburgh and its affiliated health system, UPMC. The UPCI includes 348 members from 37 academic departments who have come together to work to reduce the burden of cancer through cancer-related basic, translational, clinical, behavioral, epidemiological, prevention and control research. Total annual extramural cancer research funding (direct costs) to UPCI was $109.5 million (peer-reviewed $95M, non-peer-reviewed $14.5M) on October 1, 2009 of which $42.5M was received from the National Cancer Institute. The commitment of UPCI to transdisciplinary cancer research is exemplified by the fact that its members lead three SPORE grants (lung, head and neck, and skin cancers), eight cancer-focused P01s, two Early Detection Research Network grants, and a phase I U01. The impact of the cancer research driven by UPCI and its members can be seen in the more than 4,400 unique publications by UPCI investigators from 2004-2009 of which 45% represent collaborative efforts (17% intra-programmatic, 20% inter-programmatic, and 8% both). The integration of investigators at the main University of Pittsburgh campus with clinicians from a unique clinical care network encompassing about 40 UPMC community cancer centers across Western Pennsylvania has enabled enhanced patient access to clinical trials throughout our catchment area in a highly productive way. In 2008 a total of 11,484 patients were entered in the cancer registry. During that same year 1,158 and 2,508 patients entered interventional and non-interventional clinical trials, respectively. It is noteworthy that in 2008 30% of accruals to interventional trials were to investigator-initiated trials and 40% of accruals to interventional trials took place at UPMC community cancer centers. This renewal application requests support for twelve scientific research Programs, fifteen Shared Facilities, Protocol-Specific Research Support, Protocol Review and Monitoring System, planning and evaluation activities, developmental funds, senior leadership, staff investigators, and administration.

Public Health Relevance

UPCI is a comprehensive Cancer Center focused on cancer research, education, and care. UPCI laboratory and clinical investigators work closely together to identify improved approaches for cancer prevention, diagnosis and treatment with the common goal of reducing the burden of cancer and improving cancer care for patients who are diagnosed with this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA047904-24S3
Application #
8533415
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (M1))
Program Officer
Marino, Michael A
Project Start
1997-09-10
Project End
2015-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$50,330
Indirect Cost
$17,327
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Weir, Mark C; Shu, Sherry T; Patel, Ravi K et al. (2018) Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol 13:1551-1559
Chakraborty, Souvik; Jiang, Chang; Gau, David et al. (2018) Profilin-1 deficiency leads to SMAD3 upregulation and impaired 3D outgrowth of breast cancer cells. Br J Cancer 119:1106-1117
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Song, Xinxin; Lee, Dae-Hee; Dilly, Ashok-Kumar et al. (2018) Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex. Mol Cancer Res 16:1077-1091
Chen, Dongshi; Tong, Jingshan; Yang, Liheng et al. (2018) PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc Natl Acad Sci U S A 115:3930-3935
Teng, Yaqun; Yadav, Tribhuwan; Duan, Meihan et al. (2018) ROS-induced R loops trigger a transcription-coupled but BRCA1/2-independent homologous recombination pathway through CSB. Nat Commun 9:4115
Nguyen, Nghi C; Yee, Melissa K; Tuchayi, Abuzar M et al. (2018) Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study. Front Oncol 8:18
Hartmaier, R J; Trabucco, S E; Priedigkeit, N et al. (2018) Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 29:872-880
Palliyaguru, Dushani L; Yuan, Jian-Min; Kensler, Thomas W et al. (2018) Isothiocyanates: Translating the Power of Plants to People. Mol Nutr Food Res 62:e1700965

Showing the most recent 10 out of 1187 publications